{
  "first_published_at": "2007-08-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON079100", 
  "title": "Dopamine agonists: pathological gambling, increased libido, and hypersexuality", 
  "tags": "{\"parsed_therapeutic\": [\"neurology\", \"endocrinology-diabetology-metabolism\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Neurology\", \"Endocrinology, diabetology and metabolism\"]}", 
  "_document_number": 331, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "neurology", 
    "endocrinology-diabetology-metabolism"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Dopamine agonists: pathological gambling, increased libido, and hypersexuality</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: August 2007</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Compulsive behaviour with dopamine agonists may be dose-related<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Dopamine agonists (eg, apomorphine [APO-go], bromocriptine [Parlodel], cabergoline [Cabaser, Dostinex], levodopa, pergolide [Celance], piribedil, pramipexole [Mirapexin], quinagolide [Norprolac], and ropinirole [Adartrel&#9660;, Requip]) are used in the management of patients with Parkinson&rsquo;s disease; other uses include restless legs syndrome and endocrine disorders.</p><p>Evidence from spontaneous adverse reaction reports and the literature<cite>Dodd M, et al. Arch Neurol 2005; <strong>62</strong>: 1377&ndash;81.</cite>,<cite>Klos KJ, et al. Parkinsonism Related Disorders 2005; <strong>11</strong>: 381&ndash;86.</cite> suggest that pathological gambling and increased libido, including hypersexuality, may be rare class effects of dopamine agonists.<cite>MHRA Public Assessment Report: <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON2025151\">Dopamine agonists: Pathological gambling and increased libido are potential class effects of these drugs</a>.</cite></p><p>Product information for medicines that contain dopamine agonists or levodopa, or both, is being updated to include the following wording:</p><ul>\r\n\t\t\t<li><strong>Special warnings and precautions for use:<br>\r\n\t\t\t\t\t<br></strong>Pathological gambling, increased libido and hypersexuality have been reported in patients treated with dopamine agonists for Parkinson&rsquo;s disease, including &lt;Product/Drug name&gt;</li></ul><br><ul>\r\n\t\t\t<li><strong>Undesirable effects:<br>\r\n\t\t\t\t\t<br></strong>Patients treated with dopamine agonists for treatment of Parkinson's disease, including &lt;Product/Drug name&gt;, especially at high doses, have been reported as exhibiting signs of pathological gambling, increased libido and hypersexuality, generally reversible upon reduction of the dose or treatment discontinuation</li></ul><p>Healthcare professionals are advised to warn patients about these possible side-effects, and to inform patients to seek help from their doctor if they, their family, or their carer notice that their behaviour is unusual.</p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update August 2007; Vol 1, Issue 1: 6</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Dopamine agonists (eg, apomorphine [APO-go], bromocriptine [Parlodel], cabergoline [Cabaser, Dostinex], levodopa, pergolide [Celance], piribedil, pramipexole [Mirapexin], quinagolide [Norprolac], and ropinirole [Adartrel&#9660;, Requip]) are used in the management of patients with Parkinson&#8217;s disease; other uses include restless legs syndrome and endocrine disorders.</p><p>Evidence from spontaneous adverse reaction reports and the literature<cite>Dodd M, et al. Arch Neurol 2005; <strong>62</strong>: 1377&#8211;81.</cite>,<cite>Klos KJ, et al. Parkinsonism Related Disorders 2005; <strong>11</strong>: 381&#8211;86.</cite> suggest that pathological gambling and increased libido, including hypersexuality, may be rare class effects of dopamine agonists.<cite>MHRA Public Assessment Report: <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON2025151\">Dopamine agonists: Pathological gambling and increased libido are potential class effects of these drugs</a>.</cite></p><p>Product information for medicines that contain dopamine agonists or levodopa, or both, is being updated to include the following wording:</p><ul>\r\n\t\t\t<li><strong>Special warnings and precautions for use:<br>\r\n\t\t\t\t\t<br></strong>Pathological gambling, increased libido and hypersexuality have been reported in patients treated with dopamine agonists for Parkinson&#8217;s disease, including &lt;Product/Drug name&gt;</li></ul><br><ul>\r\n\t\t\t<li><strong>Undesirable effects:<br>\r\n\t\t\t\t\t<br></strong>Patients treated with dopamine agonists for treatment of Parkinson's disease, including &lt;Product/Drug name&gt;, especially at high doses, have been reported as exhibiting signs of pathological gambling, increased libido and hypersexuality, generally reversible upon reduction of the dose or treatment discontinuation</li></ul><p>Healthcare professionals are advised to warn patients about these possible side-effects, and to inform patients to seek help from their doctor if they, their family, or their carer notice that their behaviour is unusual.</p><p>&#160;</p><p><em>Article citation: Drug Safety Update August 2007; Vol 1, Issue 1: 6</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2007-08-01", 
  "date_last_modified": "2010-08-24", 
  "_assets": [], 
  "_item_id": 331, 
  "summary": "Compulsive behaviour with dopamine agonists may be dose-related", 
  "body": "Article date: August 2007\n\nDopamine agonists (eg, apomorphine [APO-go], bromocriptine [Parlodel], cabergoline [Cabaser, Dostinex], levodopa, pergolide [Celance], piribedil, pramipexole [Mirapexin], quinagolide [Norprolac], and ropinirole [Adartrel▼, Requip]) are used in the management of patients with Parkinson’s disease; other uses include restless legs syndrome and endocrine disorders.\n\nEvidence from spontaneous adverse reaction reports and the literature[^1], [^2] suggest that pathological gambling and increased libido, including hypersexuality, may be rare class effects of dopamine agonists. [^3]\n\nProduct information for medicines that contain dopamine agonists or levodopa, or both, is being updated to include the following wording:  \n  \n  * Special warnings and precautions for use:  \n  \nPathological gambling, increased libido and hypersexuality have been reported in patients treated with dopamine agonists for Parkinson’s disease, including <Product/Drug name>  \n  \n  \n  \n  * Undesirable effects:  \n  \nPatients treated with dopamine agonists for treatment of Parkinson's disease, including <Product/Drug name>, especially at high doses, have been reported as exhibiting signs of pathological gambling, increased libido and hypersexuality, generally reversible upon reduction of the dose or treatment discontinuation  \n  \nHealthcare professionals are advised to warn patients about these possible side-effects, and to inform patients to seek help from their doctor if they, their family, or their carer notice that their behaviour is unusual.\n\n \n\nArticle citation: Drug Safety Update August 2007; Vol 1, Issue 1: 6\n\n[^1]: Dodd M, et al. Arch Neurol 2005; 62: 1377–81.\n\n[^2]: Klos KJ, et al. Parkinsonism Related Disorders 2005; 11: 381–86.\n\n[^3]: MHRA Public Assessment Report: [Dopamine agonists: Pathological gambling and increased libido are potential class effects of these drugs](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON2025151).\n"
}